October 18, 2024
Hays names new Head of Life Sciences
Hays, the global workforce solutions and recruitment specialist, has appointed James Nyssen as Global Head of Life Sciences. The global…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
October 2, 2024
Owkin, AstraZeneca to develop AI gBRCA pre-screen solution for breast cancer
Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, and AstraZeneca, have teamed up to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitised pathology slides.
October 2, 2024
Ex CEO of Vifor Pharma joins Moderna’s Board of Directors
Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna’s Board of Directors, effective October 2, 2024.
September 30, 2024
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM
Formycon AG and its commercialization partner Fresenius Kabi jointly said Monday that the U.S. Food and Drug Administration (FDA) has approved FYB202/OtulfiTM1 (ustekinumab-aauz), a biosimilar to Stelara, for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis, the third Formycon biosimilar successfully approved by the FDA.
September 27, 2024
Affluant Medical reports net loss of €9.4 million in H1 202 as it develops three devices
Affluent Medical, a French clinical-stage medical technology company specializing in the international development and industrialization of implantable innovative medical devices, reported a net loss of €9.4 million in H1 2024, compared to a net loss of €8.0 million in the prior year period, citing several majors steps developing its three medical devices.
September 26, 2024
Oxford Drug Design gets a share of a £3 million Collaborative Discovery Programme
Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP) announced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate.
September 26, 2024
Laverock Therapeutics advances in its programmable gene silencing platform
Laverock Therapeutics, a UK-based gene-silencing company with a technology for the development of programmable advanced therapies to tackle major diseases,…
September 25, 2024
Bio-Sourcing gets €2.5M in grants and €10M in equity from the EIC Accelerator
Bio-Sourcing, a pioneering Belgian biotherapeutic company, has secured €2.5M in grants and €10M in equity from the European Innovation Council…
September 25, 2024
SLEEVER and CARBIOS globally launch world’s first Home Compost biodegradable tamper evident seal: SEELCAP ONEGO
SLEEVER®, a French family-owned group International SME and innovative leader in shrinksleeve label technology, and CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the…
September 25, 2024
Vilobelimab demonstrates significant improvement in reduction of draining tunnels
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today said that Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR